Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Pulmonary arterial hypertension, a form of high blood pressure that occurs in the lungs, is a target of research by Cedars-Sinai investigators.
News | Hypertension
Unique Cell-based Approach for Pulmonary Arterial Hypertension Shown to Be Safe

December 13, 2023 —Infusions of potentially therapeutic cells derived from the heart are safe for people with pulmonary ...

Home December 13, 2023
Home
Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of blood clots, according to a retrospective study published in Mayo Clinic Proceedings.
News | Heart Valve Technology
Use of Anticoagulant Drug after Aortic Valve Replacement Lowers Mortality Risk, Mayo Clinic Study Finds

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement h ...

Home December 12, 2023
Home
New study reveals latest data on global burden of cardiovascular disease
News | Cardiovascular Clinical Studies
New Study Reveals Latest Data on Global Burden of Cardiovascular Disease

December 11, 2023 — A world without cardiovascular disease (CVD) is possible, yet millions of lives are lost prematurely ...

Home December 11, 2023
Home
UC Gardner Neuroscience Institute
News | Stroke
UC Gardner Neuroscience Institute to Lead New National Stroke Study

December 8, 2023 — Ischemic stroke is the most common form of stroke in the U.S., affecting more than 690,000 people ...

Home December 08, 2023
Home
The DRAIN-HF study will evaluate the Aortix percutaneous mechanical circulatory support (pMCS) technology in patients with acute decompensated heart failure (ADHF) who are unresponsive to standard medical therapy.
News | Cardiovascular Clinical Studies
Procyrion Announces First Patient Enrollments in the DRAIN-HF Pivotal IDE Trial for Aortix Percutaneous Mechanical Circulatory Support Technology

December 8, 2023 — Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac ...

Home December 08, 2023
Home
Take a look at the news making top headlines during the month of November on dicardiology.com
Feature | Cardiovascular Business | By Melinda Taschetta-Millane
DAIC's Top 10 for November

November was a busy month with many FDA approvals and breaking clinical trial results. Take a look at the news making ...

Home December 05, 2023
Home
News | Cardiovascular Education
Minneapolis Heart Institute Foundation Research Advances Understanding of Health Equity and Outcomes in Fourth-Trimester Care for Women

December 4, 2023 — The Minneapolis Heart Institute Foundation (MHIF), an internationally renowned cardiovascular ...

Home December 04, 2023
Home
As coronary computed tomography angiography (CCTA) progresses towards becoming the primary imaging modality for not only diagnostic purposes, but also for clinical trial endpoints, there is a need to address the requirements for generating high-quality CCTA image data to ensure accurate and robust CAD assessments
Feature | Computed Tomography (CT) | By Andrew Michalski, PhD and Rohit Sood MD, PhD
From the Clinic to Pharmaceutical Clinical Trials: Considerations for using Coronary CT Angiography (CCTA) in Atherosclerotic Cardiovascular Disease (ASCVD) Clinical Trials

Coronary artery disease (CAD), also known as ischemic heart disease, is the most common heart disease with a prevalence ...

Home December 05, 2023
Home
Researchers have succeeded in restoring lost brain function in mouse models of stroke using small molecules that in the future could potentially be developed into a stroke recovery therapy.
News | Stroke
New Study: Lost Brain Function Restored After Stroke

December 1, 2023 — Researchers have succeeded in restoring lost brain function in mouse models of stroke using small ...

Home December 01, 2023
Home
Data from all three patients in non-randomized cohort treated with DSR 2.0 indicate safe and effective maintenance of euvolemia without the need for loop diuretics, considerable benefit in cardiorenal status and dramatic improvement in diuretic response and loop diuretic requirements up to 11 weeks post DSR treatment
News | Heart Failure
Sequana Medical Announces Positive Data from Non-randomized Cohort in US Phase 1/2a MOJAVE Study of DSR 2.0 for Treatment of Heart Failure

November 30, 2023 —  Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure an ...

Home November 30, 2023
Home
Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the first patient enrollment in the PEERLESS II study
News | Cardiovascular Clinical Studies
Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT)

November 29, 2023 —  Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home November 29, 2023
Home
Foldax, Inc., a leader in the development of innovative, polymer heart valves, today announced completion of enrollment in the Indian clinical trial of the TRIA polymer surgical mitral heart valve.
News | Cardiovascular Clinical Studies
Foldax Completes Enrollment in India Clinical Trial Evaluating TRIA Polymer Surgical Mitral Heart Valve

November 29, 2023 —  Foldax, Inc., a leader in the development of innovative, polymer heart valves, today announced ...

Home November 29, 2023
Home
Study to enroll 15 acute stroke patients across three U.S. sites
News | Stents
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

November 29, 2023 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home November 29, 2023
Home
Impella Improves Survival and Heart Recovery
News | Cardiovascular Clinical Studies
First Patient Enrolled in Abiomed’s RECOVER IV Randomized Controlled Trial of Impella as a Therapy for AMI Cardiogenic Shock

November 28, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announces the first patient in the world has been ...

Home November 28, 2023
Home
A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and All-Cause Mortality Compared to Those with the Lowest Inflammation
News | Cardiovascular Clinical Studies
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023

November 27, 2023 — Esperion announced the presentation of results from a pre-specified, exploratory analysis of CLEAR ...

Home November 27, 2023
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now